



Predictors of poor outcomes after cholecystectomy in gallstone pancreatitis: NSQIP analysis of 30-day morbidity and mortality

Jessica K. Liu¹ · Caitlyn Braschi¹ · Christian de Virgilio¹ · Junko Ozao-Choy¹ · Dennis Y. Kim¹ · Ashkan Moazzez¹

Received: 6 October 2022 / Accepted: 15 October 2022 / Published online: 31 December 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Background Contemporary nationwide outcomes of gallstone pancreatitis (GSP) managed by cholecystectomy at the index hospitalization are limited. This study aims to define the rate of 30-day morbidity and mortality and identify associated perioperative risk factors in patients undergoing cholecystectomy for GSP.

Methods Patients from the ACS-NSQIP database with GSP without pancreatic necrosis, who underwent cholecystectomy during the index hospitalization from 2017 to 2019 were selected. Factors associated with 30-day morbidity and mortality were analyzed.

Results Of the 4021 patients identified, 1375 (34.5%) were male, 2891 (71.9%) were White, 3923 (97.6%) underwent laparoscopic surgery, and 52.4 years (SD ± 18.9) was the mean age. There were 155 (3.8%) patients who developed morbidity and 15 (0.37%) who died within 30 days of surgery. In bivariate regression analysis, both 30-day morbidity and mortality were associated with older age, elevated pre-operative BUN, hypertension, chronic obstructive pulmonary disease, congestive heart failure, acute kidney injury, and dyspnea. ASA of I or II and laparoscopic surgery were protective against 30-day morbidity and mortality. In multivariable regression analysis, factors independently associated with increased 30-day morbidity included preoperative SIRS/sepsis [OR: 1.68 (95% CI: 1.01–2.79), $p=0.048$], and age [OR: 1.03 (95% CI: 1.01–1.04), $p=0.001$]. Factors associated with increased 30-day mortality included tobacco use [OR: 8.62 (95% CI: 2.11–35.19), $p=0.003$] and age [OR: 1.10 (95% CI: 1.04–1.17), $p=0.002$].

Conclusions Patients with GSP without pancreatic necrosis can undergo cholecystectomy during the index admission with very low risk of 30-day morbidity or mortality.

Keywords Gallstone pancreatitis · Cholecystectomy · Morbidity · Mortality · Acute pancreatitis · NSQIP

Introduction

Acute pancreatitis is a leading cause for gastrointestinal-related hospital admissions in the USA, and gallstone disease is the most common etiology of acute pancreatitis [1]. Cholecystectomy remains the definitive treatment for gallstone pancreatitis (GSP); however, the recommended timing of surgery has evolved [2]. The most recent evidence supports cholecystectomy during the index hospitalization for mild GSP [3–5]. Performing cholecystectomy

prior to discharge decreases the risk of patients returning with progressive or recurrent symptoms, which can lead to significant morbidity [6–8]. In fact, delayed cholecystectomy has been associated with a 31–53% risk of recurrent biliary events including pancreatitis [5, 9].

Despite the prevalence of GSP, there are few studies analyzing national data on the morbidity and mortality of cholecystectomy at index hospitalization. Given the increasing use of cholecystectomy during the index hospitalization, it is important to understand the predictors of poor surgical outcomes in order to guide risk stratification and patient selection. Therefore, this study aims to define the rate of 30-day morbidity and mortality as well as identify associated perioperative risk factors in patients undergoing cholecystectomy for GSP at the index hospitalization.

✉ Ashkan Moazzez
amoazzez@dhs.lacounty.gov

¹ Department of Surgery, Harbor-UCLA Medical Center, 1000 W. Carson Street, Bldg. F10, Torrance, CA 90505, USA

Methods

Data source and patient selection

The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database provides 30-day risk-adjusted surgical outcomes using peer-controlled, validated perioperative clinical data. The database from 2019 included 719 hospitals nationwide that participate on a voluntary basis. The NSQIP database from years 2017 to 2019 was queried for patients who underwent either laparoscopic or open cholecystectomy (CPT codes 47,600, 47,605, 47,610, and 47,562–4) for gallstone pancreatitis during their index hospitalization. Only patients with the diagnosis of gallstone pancreatitis without pancreatic necrosis were included based on the International Classification of Diseases, 10th revision (ICD-10) code K85.10, as patients with necrosis are typically subject to a different management algorithm that includes delayed cholecystectomy. Patients were included if their surgery was performed on an inpatient, non-elective basis. This study was approved by the Institutional Review Board of Lundquist Institute at Harbor-UCLA Medical Center and determined to meet the criteria for non-human subject research.

Variables

Patient demographics, comorbidities, and risk factors were collected. Comorbidities assessed were diabetes mellitus, hypertension requiring medications, congestive heart failure (CHF), renal failure, dialysis dependence, ascites, metastatic cancer, and chronic obstructive pulmonary disease (COPD). NSQIP-defined risk factors included smoking history, chronic steroid use, and recent weight loss. Additional preoperative variables included white blood cell count (WBC), blood urea nitrogen (BUN) level, dyspnea, ascites, acute kidney injury (AKI), preoperative ventilator use, preoperative systemic inflammatory response syndrome (SIRS)/sepsis, preoperative blood transfusion, and American Society of Anesthesiologists (ASA) class. The SIRS/sepsis variable spans patients with relatively mild physiologic abnormalities to septic shock. The primary outcome measures were 30-day mortality and 30-day morbidity. The variables in this study's composite morbidity variable included any of the following post-operative complications: pneumonia, unplanned intubation, ventilator use greater than 48 h, pulmonary embolism (PE), deep venous thrombosis (DVT), urinary tract infection (UTI), renal insufficiency or failure, superficial, deep or organ space surgical site infection, wound dehiscence, cardiac arrest, myocardial infarction, stroke, or post-operative SIRS/sepsis.

Analysis

Bivariate and multivariate logistic regression analyses were performed to assess whether demographics, comorbidities, and markers of preoperative end-organ dysfunction were associated with 30-day morbidity and mortality. A 2-sided $p < 0.05$ was considered statistically significant. Any variable with $p < 0.10$ in initial bivariate analysis was included in a multivariate regression analysis. The Student's t -test was used to compare continuous data, and Pearson χ^2 and Fisher's exact tests were used to compare categorical data as appropriate. SPSS V24 (IBM Corp, Armonk, New York) was used to perform statistical analysis.

Results

A total of 4021 patients with gallstone pancreatitis without necrosis underwent cholecystectomy. Of those, 1375 (34.5%) were male, 2891 (71.9%) were White, 558 (22.4%) were Hispanic, and 3923 (97.6%) underwent laparoscopic surgery. The mean age was 52.4 ± 18.9 years. There were 37 (0.9%) patients who returned to the operating room. A total of 155 (3.8%) patients developed morbidity and 15 (0.37%) died within 30 days of surgery.

In bivariate regression analysis, 30-day morbidity was associated with older age (63.6 ± 17.3 vs. 51.9 ± 18.9 , $p < 0.001$), male sex (47.1% vs. 33.7%, $p = 0.001$), BUN (16.5 ± 16.3 vs. 10.2 ± 7.7 , $p < 0.001$), higher WBC (10.3 ± 4.5 vs. 8.8 ± 3.8 , $p < 0.001$), and the following comorbid conditions: hypertension (55.5% vs. 38.9%, $p < 0.001$), COPD (11.6% vs. 2.7%, $p < 0.001$), CHF (3.9% vs. 1.1%, $P = 0.012$), AKI (4.5% vs. 0.3%, $p < 0.001$), dyspnea (7.1% vs. 2.8%, $p = 0.006$), steroid use (5.2% vs. 2.0%, $p = 0.018$), and preoperative SIRS/sepsis (34.8% vs. 19.3%, $p < 0.001$). Factors protective against 30-day morbidity were Hispanic ethnicity (9.0% vs. 14.1%, $p = 0.032$), ASA class I or II (29.7% vs. 56.5%, $p < 0.001$), laparoscopic surgery (84.5% vs. 98.1%, $p < 0.001$), and cholecystectomy performed within 3 days of admission (40.0% vs. 48.2%, $p = 0.044$) (Table 1).

Patients who had higher 30-day mortality were older (75.5 ± 13.2 vs. 52.3 ± 18.9 , $p < 0.001$), had higher rates of current tobacco use (33.3% vs. 13.9%, $p = 0.047$), and had higher pre-operative BUN (28.1 ± 22.2 vs. 10.4 ± 8.1 , $p < 0.001$). Additionally, they had higher rates of diabetes (40.0% vs. 15.0%, $p = 0.017$), hypertension (73.3% vs. 39.4%, $p = 0.007$), COPD (20.0% vs. 3.0%, $p = 0.009$), CHF (13.3% vs. 1.2%, $p = 0.014$), dialysis use (13.3% vs. 0.9%, $p = 0.008$), AKI (13.3% vs. 0.4%, $p = 0.002$), dyspnea (20.0% vs. 2.9%, $p = 0.009$), bleeding disorders (26.7% vs. 5.6%, $p = 0.009$), and lower BMI (29.4 ± 4.7 vs. 32.5 ± 8.2 ,

Table 1 Bivariate regression analysis for 30-day Morbidity and 30-day Mortality by demographics, clinical characteristics, and operative factors for patients with acute gallstone pancreatitis without necrosis who underwent cholecystectomy

Characteristics	No. 30-day morbidity (%) (n = 3866)	30-day morbidity (%) (n = 155)	p-value	No. 30-day mortality (%) (n = 4006)	30-day mortality (%) (n = 15)	p-value
Male	1302 (33.7)	73 (47.1)	0.001	1368 (34.1)	7 (46.7)	0.31
White	2774 (71.8)	117 (75.5)	0.61	2879 (83.8)	12 (85.7)	0.60
Hispanic	544 (14.1)	14 (9.03)	0.032	556 (13.9)	2 (13.3)	0.54
Diabetes	576 (14.9)	31 (20.0)	0.082	601 (15.0)	6 (40.0)	0.017
Hypertension	1502 (38.9)	86 (55.5)	<0.001	1577 (39.4)	11 (73.3)	0.007
COPD	104 (2.7)	18 (11.6)	<0.001	119 (3.0)	3 (20.0)	0.009
CHF	44 (1.1)	6 (3.9)	0.012	48 (1.2)	2 (13.3)	0.014
Dialysis	33 (0.9)	4 (2.6)	0.052	35 (0.9)	2 (13.3)	0.008
Ascites	9 (0.2)	2 (1.3)	0.065	11 (0.3)	0 (0)	1.0
Acute kidney injury	10 (0.3)	7 (4.5)	<0.001	15 (0.4)	2 (13.3)	0.002
Dyspnea	108 (2.8)	11 (7.1)	0.006	116 (2.9)	3 (20.0)	0.009
Current smoker ^a	537 (13.9)	24 (15.5)	0.57	556 (13.9)	5 (33.3)	0.047
Bleeding disorder	215 (5.6)	15 (9.7)	0.30	226 (5.6)	4 (26.7)	0.009
Metastatic cancer	12 (0.3)	0 (0)	1.0	12 (0.3)	0 (0)	1.0
Steroid use ^b	79 (2.0)	8 (5.2)	0.018	86 (2.1)	1 (6.7)	0.28
Weight loss ^c	47 (1.2)	4 (2.6)		50 (1.2)	1 (6.7)	0.18
Preop ventilator	7 (0.2)	0 (0)	1.0	7 (0.2)	0 (0)	1.0
Preop transfusion	19 (0.5)	2 (1.3)	0.19	21 (0.5)	0 (0)	0.924
Preop SIRS/sepsis	746 (19.3)	54 (34.8)	<0.001	794 (19.8)	6 (40.0)	0.059
Emergent	692 (17.9)	21 (13.5)	0.16	710 (17.7)	3 (20.0)	0.74
ASA class I or II	2184 (56.5)	46 (29.7)	<0.001	2230 (55.7)	0 (0)	<0.001
Laparoscopic surgery	3792 (98.1)	131 (84.5)	<0.001	3911 (97.6)	12 (80.0)	0.005
Cholecystectomy within 3 days of admission	1865 (48.2)	62 (40.0)	0.044	1921 (48.0)	6 (40.0)	0.379
Age, mean (SD), years	51.94 (18.85)	63.56 (17.27)	<0.001	52.3 (18.9)	75.5 (13.2)	<0.001
Pre-operative BUN, mean (SD)	10.24 (7.65)	16.49 (16.27)	<0.001	10.4 (8.1)	28.1 (22.2)	<0.001
Pre-operative WBC, mean (SD)	8.79 (3.77)	10.26 (4.49)	<0.001	8.8 (3.8)	9.48 (3.0)	0.42
BMI, mean (SD), kg/m ²	32.51 (8.15)	32.33 (7.97)	0.79	32.51 (8.15)	29.35 (4.66)	0.025

COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; ASA, American Society of Anesthesiologists; SD, standard deviation; WBC, white blood cells; BUN, blood urea nitrogen; BMI, body mass index, *within 72 h of admission; ^acurrent smoker within 1 year; ^bsteroid use for chronic condition; ^c> 10% loss body weight in last 6 months

Bolded values represent statistical significance

$p = 0.025$). ASA class I or II (55.7% vs. 0%, $p < 0.001$) and laparoscopic surgery (97.6% vs. 80.0%, $p = 0.005$) were associated with lower 30-day mortality (Table 1).

In multivariable regression analysis, factors independently associated with higher 30-day morbidity included pre-operative SIRS/sepsis [OR: 1.68 (95% CI: 1.01–2.79), $p = 0.048$], and age [OR: 1.03 (95% CI: 1.01–1.04), $p = 0.001$], whereas laparoscopic surgery [OR: 0.10 (95% CI: 0.055–0.20), $p < 0.001$] was associated with lower morbidity. Factors associated with higher 30-day mortality included tobacco use [OR: 8.62 (95% CI: 2.11–35.19), $p = 0.003$] and age [OR: 1.10 (95% CI: 1.04–1.17), $p = 0.002$], whereas laparoscopic surgery was similarly associated with lower mortality [OR: 0.13 (95% CI: 0.031–0.57), $p = 0.007$] (Table 2).

Discussion

In this large national study of patients with gallstone pancreatitis without pancreatic necrosis who underwent cholecystectomy during the index admission, 30-day morbidity and mortality were notably low at 3.8% and 0.37%, respectively. The exclusion of patients with pancreatic necrosis in this cohort could contribute to the low overall morbidity and mortality, as severe gallstone pancreatitis, though less common, has an associated mortality risk up to 19% [10]. Our findings are consistent with prior studies demonstrating that patients with mild gallstone pancreatitis who undergo cholecystectomy have a relatively low risk for mortality if they undergo surgery at the index hospitalization.

Table 2 Multivariate logistic regression analysis of factors associated with 30-day morbidity and mortality in patients with acute gallstone pancreatitis without necrosis who underwent cholecystectomy

Characteristics	30-day morbidity		30-day mortality	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Male	0.93 (0.59–1.46)	0.74	N/A	N/A
Hispanic	1.05 (0.57–1.96)	0.87	N/A	N/A
Diabetes	0.63 (0.34–1.15)	0.63	1.06 (0.28–3.99)	0.93
Hypertension	0.79 (0.47–1.33)	0.37	0.45 (0.12–1.76)	0.45
COPD	1.83 (0.78–4.30)	0.17	0.85 (0.14–5.23)	0.86
CHF	1.18 (0.33–4.23)	0.8	1.67 (0.24–11.71)	0.61
Dialysis	1.41 (0.31–6.41)	0.66	2.65 (0.19–36.20)	0.47
Ascites	6.32 (0.65–61.46)	0.11	N/A	N/A
Acute kidney injury	3.30 (0.61–17.85)	0.17	3.42 (0.19–63.03)	0.41
Dyspnea	0.95 (0.34–2.66)	0.92	1.09 (0.18–6.71)	0.93
Current smoker ^a	N/A	N/A	8.62 (2.11–35.19)	0.003
Steroid use ^b	1.43 (0.52–3.92)	0.49	N/A	N/A
Bleeding disorder	0.77 (0.34–1.74)	0.53	1.97 (0.53–7.37)	0.31
Preop SIRS/sepsis	1.68 (1.01–2.79)	0.048	1.70 (0.50–5.80)	0.4
ASA class I or II	0.55 (0.33–0.93)	0.025	0	0.98
Laparoscopic surgery	0.10 (0.055–0.20)	< 0.001	0.13 (0.031–0.57)	0.007
Cholecystectomy within 3 days of admission	0.84 (0.54–1.33)	0.47	N/A	N/A
Age, mean (SD)	1.03 (1.01–1.04)	0.001	1.10 (1.04–1.17)	0.002
Pre-operative BUN, mean (SD)	1.01 (1.00–1.04)	0.14	1.03 (0.99–1.07)	0.17
Pre-operative WBC, mean (SD)	1.04 (0.99–1.09)	0.12	N/A	N/A
BMI, mean (SD)	N/A	N/A	1.00 (0.92–1.09)	0.98

OR, odds ratio; CI, confidence interval; SD, standard deviation; N/A, not applicable (not included in model); COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; ASA, American Society of Anesthesiologists; WBC, white blood cells; BUN, blood urea nitrogen; BMI, body mass index; ^acurrent smoker within 1 year; ^bsteroid use for chronic condition

Bolded values represent statistical significance

The findings of our study demonstrating low short-term morbidity and mortality rates using recent nationwide data are consistent with literature that supports early cholecystectomy for gallstone pancreatitis [4–7]. In the PONCHO trial, a large multicentered randomized prospective study of mild gallstone pancreatitis, same-admission cholecystectomy reduced perioperative morbidity specifically readmissions for recurrent gallstone disease [3]. In a smaller prospective study, mild gallstone pancreatitis patients who underwent early cholecystectomy (within 48 h after admission) did not have increased risk for perioperative complications compared to patients who had cholecystectomy performed later in their hospitalization [7]. Jee et al. performed a randomized prospective trial that found an 8% post-operative complication rate after early laparoscopic cholecystectomy. However, over 80% of these complications were mild surgical site infections, and there were no mortalities [5]. Using a large national database, we confirm that morbidity and mortality are indeed rare events among patients with biliary pancreatitis. Therefore, cholecystectomy during the index hospitalization appears safe, and may be even safer with a laparoscopic approach.

Although a number of factors associated with increased risk for morbidity and mortality in acute pancreatitis have been implicated [11, 12], specific risk factors for post-operative complications following cholecystectomy among patients with gallstone pancreatitis have not been clearly identified. In the present study, we identify an association between preoperative SIRS/sepsis and short-term postoperative morbidity. Overall, 19.8% of the total patients in our study had preoperative SIRS/sepsis. Of note, SIRS and sepsis were categorized under one variable, which the two could not be differentiated in this study. However, sepsis in association with gallstone pancreatitis should raise suspicion for concomitant cholangitis or cholecystitis. While concomitant cholangitis is uncommon, with rates reported as low as 3% [13], and concomitant cholecystitis seen in up to 46% of patients with biliary pancreatitis [14], these patients should be managed appropriately with antibiotics, and for cholangitis, with urgent endoscopic retrograde cholangiopancreatography, prior to surgical intervention. Older age was also found to be a key risk factor for post-operative 30-day morbidity and mortality. Older patients undergoing cholecystectomy have been found to have

higher rates of complications and increased hospital length of stay compared to younger patients [15]. Specifically, an age of 75 years or greater has been a reported risk factor for significantly worse outcomes in pancreatitis [16], and age is often included in risk stratification tools [17]. Thus, the findings of older age increasing risk of 30-day morbidity and mortality after cholecystectomy for gallstone pancreatitis are consistent with current evidence.

Additionally, smoking tobacco was identified as an independent risk factor for 30-day mortality following cholecystectomy for gallstone pancreatitis, a novel finding that has not been identified. Smoking within 1 year of any major surgery is associated with risk for post-operative vascular and respiratory events as well as for 30-day mortality [18]. Selvarajah et al. reported that active smokers who undergo cholecystectomy for benign gallbladder disease are at significantly greater risk of developing wound complications and longer hospital stays [19]. Smoking is known to cause more severe pancreatitis, likely due to the effect of nicotine, which disrupts signal transduction pathways in pancreatic acinar cells, and ultimately impairs pancreatic blood flow [20]. Future studies are needed to validate the association between smoking and mortality.

This study was limited by the use of a large retrospective database and thus constrained by the variables available through the database. Specifically, details such as the underlying causes of pre-operative sepsis, causes of death, and complications specific to cholecystectomies were not available. Diagnoses used in this study could not be validated nor was there information on how certain diagnoses were made. Additionally, clinical prognostic scores using published tools for pancreatitis severity could not be calculated given missing data. NSQIP data is populated voluntarily by participating institutions, and therefore may not be generalizable to all hospital settings and patient populations. Further research comparing these findings with cohorts managed non-operatively or with interval surgery is warranted to validate the findings of this present study and to determine whether there are other factors that may justify initial non-operative management of non-necrotic gallstone pancreatitis.

Conclusion

In gallstone pancreatitis without necrosis, patients can undergo cholecystectomy during the index admission with very low risk of 30-day morbidity or mortality. Older age, smoking status, and presence of pre-operative SIRS/sepsis should be considered when weighing the risk and benefits of initial surgery versus non-surgical management strategies.

Acknowledgements The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not been verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Author's contributions All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Ashkan Moazzez, Jessica K. Liu, and Caitlyn Braschi. The first draft of the manuscript was written by Jessica K. Liu and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability The data that support the findings of this study are available from the corresponding author, Ashkan Moazzez, upon reasonable request.

Declarations

Conflict of interests The authors declare no competing interests.

References

1. Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144(6):1252–1261. <https://doi.org/10.1053/J.GASTRO.2013.01.068>
2. Cucher D, Kulvatunyou N, Green DJ, Jie T, Ong ES (2014) Gallstone pancreatitis: a review. *Surg Clin N Am* 94(2):257–280. <https://doi.org/10.1016/J.SUC.2014.01.006>
3. da Costa DW, Bouwense SA, Schepers NJ et al (2015) Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 386(10000):1261–1268. [https://doi.org/10.1016/S0140-6736\(15\)00274-3](https://doi.org/10.1016/S0140-6736(15)00274-3)
4. Dubina ED, de Virgilio C, Simms ER et al (2018) Association of early vs delayed cholecystectomy for mild gallstone pancreatitis with perioperative outcomes. *JAMA Surg* 153(11):1057–1059. <https://doi.org/10.1001/JAMASURG.2018.2614>
5. Jee SL, Jarmin R, Lim KF, Raman K (2018) Outcomes of early versus delayed cholecystectomy in patients with mild to moderate acute biliary pancreatitis: a randomized prospective study. *Asian J Surg* 41(1):47–54. <https://doi.org/10.1016/J.ASJSUR.2016.07.010>
6. Gurusamy KS, Nagendran M, Davidson BR (2013) Early versus delayed laparoscopic cholecystectomy for acute gallstone pancreatitis. *Cochrane Database Syst Rev* (9):CD010326. <https://doi.org/10.1002/14651858.CD010326.pub2>
7. Aboulian A, Chan T, Yaghoobian A et al (2010) Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis: a randomized prospective study. *Ann Surg* 251(4):615–619. <https://doi.org/10.1097/SLA.0B013E3181C38F1F>
8. Mueck KM, Wei S, Pedroza C et al (2019) Gallstone pancreatitis: admission versus normal cholecystectomy—a randomized trial (Gallstone PANC Trial). *Ann Surg* 270(3):519–527. <https://doi.org/10.1097/SLA.0000000000003424>
9. Ito K, Ito H, Whang EE (2008) Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines? *J Gastrointest Surg* 12(12):2164–2170. <https://doi.org/10.1007/S11605-008-0603-Y/TABLES/6>
10. Gullo L, Migliori M, Oláh A et al (2002) Acute pancreatitis in five European countries: etiology and mortality. *Pancreas* 24(3):223–227. <https://doi.org/10.1097/00006676-200204000-00003>

11. Ranson JH, Rifkind KM, Roses DF et al (1974) Objective early identification of severe acute pancreatitis. *Am J Gastroenterol* 61(6):443–451
12. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA (2008) The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 57(12):1698–1703. <https://doi.org/10.1136/GUT.2008.152702>
13. Chang L, Lo SK, Stabile BE et al (1998) Gallstone pancreatitis: a prospective study on the incidence of cholangitis and clinical predictors of retained common bile duct stones. *Am J Gastroenterol* 93(4):527–531. https://doi.org/10.1111/J.1572-0241.1998.159_B.X
14. Demir U, Yazici P, Bostanci Ö et al (2014) Timing of cholecystectomy in biliary pancreatitis treatment. *Ulusal Cerrahi Dergisi* 30(1):10–13. <https://doi.org/10.5152/UCD.2014.2401>
15. Vaccari S, Lauro A, Cervellera M et al (2019) Cholecystectomy for acute cholecystitis in octogenarians: impact of advanced age on postoperative outcome. *Minerva Chir* 74(4):289–296. <https://doi.org/10.23736/S0026-4733.19.07891-X>
16. Frey CF, Zhou H, Harvey DJ, White RH (2006) The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994–2001. *Pancreas* 33(4):336–344. <https://doi.org/10.1097/01.mpa.0000236727.16370.99>
17. Żorniak M, Beyer G, Mayerle J (2019) Risk stratification and early conservative treatment of acute pancreatitis. *Visc Med* 35(2):82–89. <https://doi.org/10.1159/000497290>
18. Musallam KM, Rosendaal FR, Zaatari G et al (2013) Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. *JAMA Surg* 148(8):755–762. <https://doi.org/10.1001/jamasurg.2013.2360>
19. Selvarajah S, Ahmed AA, Schneider EB et al (2014) Cholecystectomy and wound complications: smoking worsens risk. *J Surg Res* 192(1):41–49. <https://doi.org/10.1016/J.JSS.2014.06.014>
20. Ye X, Lu G, Huai J, Ding J (2015) Impact of smoking on the risk of pancreatitis: a systematic review and meta-analysis. *PLoS ONE* 10(4):e0124075. <https://doi.org/10.1371/JOURNAL.PONE.0124075>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.